Methotrexate for knee osteoarthritis with joint lining inflammation seen on ultrasound
Tests methotrexate against placebo in people with knee osteoarthritis and ultrasound-confirmed synovitis.
Key facts
- Who runs it
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Where
- Dhaka, BangladeshSee the site
- Trial code
- Registry title
- Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 70 people, planned
- Started
- 30 Jul 2025
- Planned end
- 30 Aug 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Methotrexate (MTX)
- Placebo
- Record updated
- 12 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with primary knee osteoarthritis who have inflammation of the knee joint lining (synovitis) seen on ultrasound. It tests methotrexate against a placebo.
- Age
- 40 to 70 years
- Sex
- Men and women
- Disease stage
- Knee osteoarthritis that meets the American College of Rheumatology (ACR) clinical and X-ray criteria. Kallgren-Lawrence grade 2 to 3 on X-ray. Knee pain on most days for at least 6 months, with a pain VAS score of at least 40mm.
- Earlier treatment
- No corticosteroids into the joint, muscle or by mouth in the previous 4 weeks. No disease modifying agents (e.g. hydroxychloroquine or sulfasalazine) in the previous 3 months. No past knee joint surgery.
- Biomarker or test result
- Knee synovitis seen on musculoskeletal ultrasound.
Main reasons for not taking part
- Any known inflammatory arthritis
- BMI >= 40 kg/m2
- Abnormal kidney, liver or blood function, including active hepatitis B or C, or creatinine clearance <35 ml
- Severe knock-knee deformity (angle > 30°) or Charcot joint
- Allergy to MTX, or being pregnant or breastfeeding
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Men and women aged between 40 to 70 years
- Patients fulfilling American College of Rheumatology (ACR) clinical and radiological criteria for knee OA. (knee pain + at least 3 of 5 that not including "no palpable warmth")
- Knee pain on most days for at least 6 months, with a pain VAS of at least 40mm
- Radiological grading of OA with Kallgren-Lawrence grade of 2 to 3
- Patients with the presence of knee synovitis in Musculoskeletal ultrasound
Who cannot take part
- Use of intra-articular, intramuscular or oral corticosteroids in previous 4 weeks
- History knee joint surgery, Charcot joint
- Use of any disease modifying agents (e.g. hydroxychloroquine or sulfasalazine) in previous 3 months
- Allergic to MTX
- Abnormal renal (e.g. abnormal renal function Creatinine clearance <35 ml) hepatic (including active hepatitis B, hepatitis C, abnormal liver function), hematological (e.g. white cell count < 4 × 109/L, platelets <100 ×109/L, or hemoglobin < 9 g/dL), function
- Any known inflammatory arthritis
- BMI >= 40 kg/m2
- Severe valgus knee deformity (angle of genu valgum > 30°)
- Pregnant or lactating women
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 70 years old?
Where in Bangladesh
- Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshDhaka, BangladeshContact: Akash Ahmed AlifTaking people
About the trial
What the trial wants to find out
Background:
Read full original descriptionShow less
Osteoarthritis (OA) is a leading cause of disability worldwide, with limited treatment options and many patients suffering from chronic pain. Modern imaging has revealed that OA involves complex changes in cartilage, subchondral bone, and synovium. Pain in OA is often linked to synovitis, which is common in the condition. Methotrexate (MTX), a proven treatment for synovitis in inflammatory arthritis like rheumatoid arthritis and has a well-known safety profile. The proposal suggests that using MTX may have potential to treat symptomatic knee OA with USG (musculoskeletal ultrasound) proven synovitis by reducing synovitis and as a result, alleviate pain.
Objectives:
To assess the role of methotrexate in primary knee osteoarthritis associated with ultrasound proven synovitis.
Methods:
This randomized Controlled trial will be conducted in the department of Rheumatology, Bangladesh Medical University (BMU) from July 2025 to June 2026. A total of 70 patients will be enrolled with primary knee OA diagnosed on the basis of ACR Criteria for Knee OA with informed written consent. MSK USG examinations of knee joint and scoring (OMERACT SCORE) will be performed to detect synovitis by a rheumatologist expert in MSK US. Then randomization will be done into group A and group B following a randomization table, each consisting of 35 patients. Consecutive sampling techniques will be followed. One group will receive MTX (start with 15 mg per week for the first 2 weeks then increase to 20 mg and continue for the remaining period if tolerated) and Both groups of patients will be allowed to take NSAIDs on a requirement basis with documentation and follow non-pharmacological treatment of OA. At the end of 3rd and 6th month pain and functional status will be assessed by WOMAC, VAS and quality of life will be assessed by using Bangla version of SF-12. At the end of 6th month improvement of synovitis will be seen by MSK USG of involved knees with OMERACT scoring. Primary endpoint for efficacy will be assessed at the end of 24th week by WOMAC. Secondary endpoints will be determined by VAS and SF-12. Adverse effects will be assessed by history, physical examinations and investigations. The data will be analyzed by using the latest version SPSS software (Version 29). Results will be recorded using means and standard deviations. Results will be compared among two groups with a 95% confidence interval and a p- value of < 0.05 will be considered statistically significant. The degrees of statistical significance between groups will be analyzed by unpaired t test (for quantitative normally distributed data) and Mann Whitney U test if there is skewed distribution. Qualitative data in between groups will be analyzed by the chi square test. Probabilities of associations will be assessed by calculating Pearson's rank correlation coefficient. P-value <0.05 will be regarded as statistically significant. The nature, purpose and implication of the study as well as the entire spectrum of benefits and risks of study will be explained to the patients. Privacy and confidentiality of the subject will be maintained. Each patient will enjoy the right to participate and or withdraw from the study at any point of the study period. Ethical clearance will be obtained from the institutional Review Board (IRB) of BMU.
The 2 groups in the trial
- Methotrexate (MTX)Existing treatment, for comparison
As it will be a double blinded study , the investigator and the patient is unable to know if the drug is MTX or placebo
- PlaceboPlacebo, for comparison
As it will be a double blinded study , the investigator and the patient is unable to know if the drug is MTX or placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Role of Methotrexate in Ultrasound Proven Synovitis in Patients With Knee Osteoarthritis : A Randomized Controlled Trial
- Plain-language title
- Methotrexate for knee osteoarthritis with joint lining inflammation seen on ultrasoundGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07161336, who can take part
- Record updated
- 12 September 2025